LXRX
What one share of Lexicon Pharmaceuticals holds
Pharmaceutical Preparations
We are a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA® (sotagliflozin):
Lexicon Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.11 |
|---|---|
| Profit | −$0.16 |
| Cash and investments | $0.09 |
| Debt | $0.12 |
| Book value | $0.39 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.27 | $0.00 | −$1.69 | — | $1.61 |
| 2017 | — | −$1.17 | $0.00 | −$1.76 | — | $0.65 |
| 2018 | — | −$1.14 | $0.00 | −$1.41 | — | −$0.25 |
| 2019 | — | $1.16 | $0.00 | $0.97 | — | $0.81 |
| 2020 | — | −$0.53 | $0.00 | −$1.29 | — | $1.41 |
| 2021 | $0.00 | −$0.60 | $0.01 | −$0.61 | — | $0.78 |
| 2022 | $0.00 | −$0.62 | $0.01 | −$0.54 | — | $0.62 |
| 2023 | $0.01 | −$0.80 | $0.00 | −$0.73 | — | $0.38 |
| 2024 | $0.10 | −$0.63 | $0.00 | −$0.56 | — | $0.40 |
| 2025 | $0.14 | −$0.14 | $0.00 | −$0.19 | — | $0.29 |